Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRENE.L Regulatory News (RENE)

  • There is currently no data for RENE

Total Voting Rights

27 Dec 2006 07:01

ReNeuron Group plc27 December 2006 27 December 2006 (ReNeuron Group plc "The Company") Total Voting Rights For the purposes of the transitional provisions of the Financial ServicesAuthority's Disclosure and Transparency Rules, the Company's total issued sharecapital at the date of this notice is £1,185,241. The Company's issued share capital consists of 118,524,100 ordinary shares of 1peach, with one voting right per share. There are no shares held in treasury. The total number of voting rights in the Company is therefore 118,524,100. The above figure of 118,524,100 may be used by shareholders as the denominatorfor the calculations by which they will determine if they are required to notifytheir interest in, or a change to their interest in, the Company, under theDisclosure and Transparency Rules. For further information contact:ReNeuron Group plcMichael Hunt, CEO Tel: 44 (0)1483 302 560 Financial DynamicsDavid Yates Tel: 44 (0)20 7831 3113Nicola Daley This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
2nd Sep 20247:00 amRNSCancellation - ReNeuron Group Plc
30th Aug 20247:00 amRNSCorporate update and AIM cancellation
2nd Aug 202412:25 pmRNSCorporate Update
26th Jun 20243:33 pmRNSChange of Registered Address
5th Jun 20243:36 pmRNSCreditor’s decision on Administrators' Proposals
17th May 202412:45 pmRNSPublication of Joint Administrators' Proposals
8th May 20247:00 amRNSUpdate on Administration Process
17th Apr 202411:30 amRNSDirectorate Change
20th Mar 20243:43 pmRNSAppointment of Administrators
20th Mar 202412:30 pmRNSIntention to Appoint Administrators
1st Mar 20247:00 amRNSBlock Listing Review & Total Voting Rights
5th Feb 20242:30 pmRNSSuspension - ReNeuron Group plc
5th Feb 20242:30 pmRNSCorporate update and suspension of trading on AIM
27th Nov 20238:53 amEQSEdison issues update on ReNeuron Group (RENE): H124 results reaffirm focus on CustomEX™
8th Nov 20237:01 amRNSInterim Results for the six months ended 30 Sept
8th Nov 20237:00 amRNSReNeuron presents in vivo data at Cell 2023
4th Sep 20237:00 amRNSR&D Update
1st Sep 20237:00 amRNSBlock Listing Review & Total Voting Rights
29th Aug 20237:00 amRNSDirector declaration
22nd Aug 202310:34 amRNSResult of AGM
24th Jul 20235:20 pmRNSNotice of AGM
12th Jul 202311:57 amRNSShare Purchase by Chief Financial Officer
16th Jun 20235:12 pmRNSShare Purchase by Senior Independent NED
16th Jun 20232:26 pmRNSShare Purchase by Executive Chairman
16th Jun 20237:00 amRNSPosting of Annual Report & Accounts
5th Jun 20234:30 pmRNSHolding(s) in Company
25th May 20237:00 amRNSUnaudited Preliminary Results
18th May 20237:00 amRNSNotice of Results
17th May 20238:56 amRNSHolding(s) in Company
27th Apr 20238:18 amRNSHolding(s) in Company
6th Apr 20234:17 pmRNSShare Purchase by Senior Independent NED
3rd Apr 20237:00 amRNSNew Scientific Advisory Board
28th Mar 20232:23 pmRNSDirector/PDMR Shareholding
23rd Mar 20237:00 amRNSChange of adviser
13th Mar 20237:00 amRNSReNeuron to present at Advanced Therapies 2023
9th Mar 20234:03 pmRNSHolding(s) in Company
3rd Mar 20239:37 amRNSShare Purchase by Chief Financial Officer
1st Mar 20237:01 amRNSBlock listing application
1st Mar 20237:00 amRNSBlock Listing Review & Total Voting Rights
24th Feb 202311:20 amRNSDirector Share Purchases
15th Feb 20237:00 amRNSGrant of Options
30th Jan 20234:38 pmRNSDirector/PDMR Shareholding
27th Jan 202311:05 amRNSSecond Price Monitoring Extn
27th Jan 202311:00 amRNSPrice Monitoring Extension
24th Jan 202310:55 amRNSShare Purchase by Chief Financial Officer
23rd Jan 20233:04 pmRNSShare Purchase by Executive Chairman
19th Jan 20237:00 amRNSCompany restructuring update
3rd Jan 20237:02 amRNSTotal Voting Rights
3rd Jan 20237:00 amRNSDirectorate Change
12th Dec 20222:31 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.